Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Tapolca – page 19

245 clinical trials in Tapolca, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tapolca at a glance
245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

245 trials in Tapolca

Open in trial search

Study on the Effects of AZD5462 for Patients with Stable Chronic Heart Failure

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5462
  • Sponsor:Astrazeneca AB

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Long-Term Safety and Efficacy of ARO-APOC3 for Adults with Mixed Dyslipidemia

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Rheumatoid arthritis

Not recruiting

Study on Nipocalimab and Certolizumab for Patients with Active Rheumatoid Arthritis After Advanced Therapy

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:Janssen - Cilag International

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing MK-7684A and Pembrolizumab for Patients with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Gingival bleeding+1

Not recruiting

Study on Tranexamic Acid Oral Solution for Preventing Bleeding in Patients on Blood Thinners Undergoing Tooth Extraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tranexamic Acid
  • Sponsor:Hyloris Developments

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hidradenitis

Not recruiting

Study on Izokibep for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Tapolca

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate new treatment options for improving cardiopulmonary outcomes in patients.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Bronchodilator Treatment

The research examines the comparative effectiveness of combination therapies including budesonide, glycopyrronium, and formoterol in treating COPD, with special attention to severe cardiopulmonary manifestations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.